Frankfurt
11.03.26 | 17:30
0,220 Euro
+62,36 % +0,085
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.03. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11 | 191 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 4, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2025 | 305 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: Pain Project ACD440 Granted Orphan Drug Status in the EU | 828 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 24, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous... ► Artikel lesen | |
| 03.02. | AlzeCure Pharma: AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026 | 743 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 02.02. | AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam | 1.095 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.12.25 | AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease | 387 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system... ► Artikel lesen | |
| 11.11.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 291 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen | |
| 14.10.25 | AlzeCure Pharma: Response Letter to Previous Article Published about Alzstatin's Unique Mode of Action Against Alzheimer's | 624 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 08.09.25 | AlzeCure Pharma: Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025 | 366 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 04.09.25 | AlzeCure Pharma: Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference | 387 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.08.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2025 | 463 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's... ► Artikel lesen | |
| 20.08.25 | AlzeCure Pharma: AlzeCure Appoints Cecilia Wadell as New Head of Development | 486 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.08.25 | AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs | 469 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 11.08.25 | New last trading day for paid subscription shares (BTA) of AlzeCure Pharma AB | 332 | GlobeNewswire | At the request of AlzeCure Pharma AB, the last trading day in AlzeCure Pharma AB's paid subscription shares will be changed from 2025-08-14 to 2025-08-13.
Instrument:
Paid subscription... ► Artikel lesen | |
| 05.08.25 | AlzeCure Pharma: New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference | 463 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 29.07.25 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 586 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 24.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option | 437 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 23.07.25 | AlzeCure Pharma: AlzeCure's Rights Issue Oversubscribed According to Preliminary Results | 388 | ACCESS Newswire | THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, BELARUS, RUSSIA... ► Artikel lesen | |
| 21.07.25 | AlzeCure Pharma: AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference | 420 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 21, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 16.07.25 | AlzeCure Pharma: AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue | 366 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 429,65 | +1,00 % | Schlussglocke: Erholung stockt, Öl-Preise auf Achterbahnfahrt - Vertex top, Boeing schwach | Nach starken Vorgaben vom Vortag ist die Erholungsbewegung an der Wall Street wieder ins Stocken geraten. Sowohl der Dow Jones als auch der S&P 500 gingen mit leichten Verlusten aus dem Handel. Mit... ► Artikel lesen | |
| VIATRIS | 12,015 | -0,62 % | Dividendenbekanntmachungen (09.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANSIX INC US00773T1016 0,16 USD 0,1377 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2496 EUR ALPHABET INC CDR CA02080K1049 0... ► Artikel lesen | |
| ALTIMMUNE | 3,276 | -0,43 % | Altimmune, Inc. - 10-K, Annual Report | ||
| OPKO HEALTH | 1,025 | +1,75 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,845 | +1,25 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| JAGUAR HEALTH | 0,550 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts | SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 12,615 | -1,45 % | Aurinia targets $305M-$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development | ||
| KIORA PHARMACEUTICALS | 2,150 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference | Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life... ► Artikel lesen | |
| LIPOCINE | 8,960 | +10,48 % | Lipocine GAAP EPS of -$1.69, revenue of $1.97M | ||
| ACLARIS THERAPEUTICS | 2,992 | -3,95 % | Aclaris Therapeutics, Inc. - 8-K, Current Report | ||
| PHOTOCURE | 6,140 | -3,76 % | Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions | OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 22,500 | +0,90 % | Eurobio Scientific: 2025 FY revenue | FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 millionDeployment of the Group's strategy: Proprietary products: 35% of revenueInternationalization:... ► Artikel lesen | |
| MEDICURE | 0,585 | 0,00 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025 | WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 40,015 | +0,98 % | DAX-Check LIVE: Adidas, Aroundtown, Bayer, Bilfinger, Continental, Redcare, Sixt, Symrise, Traton | Nach dem deutlichen Rückschlag vom Vortag steht der DAX vor einem möglichen Stabilisierungsversuch. Erste Indikationen deuten auf einen nahezu unveränderten Handelsstart hin. Hoffnung kommt von der... ► Artikel lesen | |
| MERCK KGAA | 111,00 | 0,00 % | Schwacher Dollar und Generika: Merck erwartet Gewinnrückgang | Darmstadt - Der Darmstädter Pharma- und Technologiekonzern Merck stellt sich wegen harter Konkurrenz und des schwachen US-Dollars auf schwierige Zeiten ein. 2026 dürfte das operative Ergebnis zurückgehen... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +62,36 % bei einem Aktienkurs von 0,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.